Prospective Research Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 4

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $200K

  • Investors
  • 5

Prospective Research General Information

Description

Developer of a feed-incorporated preventative disease management technology designed for antibiotic discovery. The company's technology develops adaptive microbiome modulators by using chemical communications to spur Streptomyces bacteria, enabling researchers to optimize the production of novel antibiotics.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Pharmaceuticals
Primary Office
  • 376 Hale Street
  • Beverly, MA 01915
  • United States
+1 (978) 000-0000

Prospective Research Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Prospective Research Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 12-Aug-2022 $200K 00.000 Completed Generating Revenue
3. Early Stage VC (Series A) 20-Mar-2019 00.00 00.000 00.00 Completed Generating Revenue
2. Seed Round 31-Jul-2017 $416K $516K 00.000 Completed Startup
1. Accelerator/Incubator 15-Aug-2015 $100K $100K Completed Startup
To view Prospective Research’s complete valuation and funding history, request access »

Prospective Research Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Prospective Research’s complete cap table history, request access »

Prospective Research Patents

Prospective Research Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11447742-B2 Compositions and methods for activation and overexpression of secondary metabolites in microorganisms Active 09-Feb-2016 00000000
US-20180346871-A1 Compositions and methods for activation and overexpression of secondary metabolites in microorganisms Active 09-Feb-2016 00000000

Prospective Research Executive Team (4)

Name Title Board Seat Contact Info
Dakota Hamill Co-Founder, President, Board Member & Chief Executive Officer
William Liao Advisor
You’re viewing 2 of 4 executive team members. Get the full list »

Prospective Research Board Members (5)

Name Representing Role Since
Aileen Rubio Ph.D Self Board Member 000 0000
Dakota Hamill Prospective Research Co-Founder, President, Board Member & Chief Executive Officer 000 0000
Justin Burns Ph.D Self Board Member 000 0000
You’re viewing 3 of 5 board members. Get the full list »

Prospective Research Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prospective Research Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Morningside Group Venture Capital Minority 000 0000 000000 0
HATCH Accelerator/Incubator Minority 000 0000 000000 0
North Shore InnoVentures Accelerator/Incubator Minority 000 0000 000000 0
SOSV Venture Capital Minority 000 0000 000000 0
RebelBio Accelerator/Incubator Minority 000 0000 000000 0
To view Prospective Research’s complete investors history, request access »